These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11996085)

  • 1. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters.
    Agrawal AK; Agrawal A; Pal A; Guru PY; Gupta CM
    J Drug Target; 2002 Feb; 10(1):41-5. PubMed ID: 11996085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles.
    Guru PY; Agrawal AK; Singha UK; Singhal A; Gupta CM
    FEBS Lett; 1989 Mar; 245(1-2):204-8. PubMed ID: 2538359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections.
    Gupta CM; Haq W
    Methods Enzymol; 2005; 391():291-304. PubMed ID: 15721387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.
    Berman JD; Hanson WL; Chapman WL; Alving CR; Lopez-Berestein G
    Antimicrob Agents Chemother; 1986 Dec; 30(6):847-51. PubMed ID: 3813512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters.
    Maes L; Germonprez N; Quirijnen L; Van Puyvelde L; Cos P; Vanden Berghe D
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2056-60. PubMed ID: 15155199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannosylated liposomes bearing Amphotericin B for effective management of visceral Leishmaniasis.
    Rathore A; Jain A; Gulbake A; Shilpi S; Khare P; Jain A; Jain SK
    J Liposome Res; 2011 Dec; 21(4):333-40. PubMed ID: 21612342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani.
    Kumar R; Sahoo GC; Pandey K; Das V; Das P
    Drug Deliv; 2015 May; 22(3):383-8. PubMed ID: 24601828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal amphotericin B in the treatment of visceral leishmaniasis.
    Croft SL; Davidson RN; Thornton EA
    J Antimicrob Chemother; 1991 Oct; 28 Suppl B():111-8. PubMed ID: 1778888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis.
    Gupta S; Dube A; Vyas SP
    J Drug Target; 2007 Jul; 15(6):437-44. PubMed ID: 17613662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis.
    Khatik R; Dwivedi P; Khare P; Kansal S; Dube A; Mishra PR; Dwivedi AK
    Expert Opin Drug Deliv; 2014 May; 11(5):633-46. PubMed ID: 24606222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A; Singh N; Sundar S; Singh N
    Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileishmanial activity of nano-amphotericin B deoxycholate.
    Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
    J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
    Khan MA; Nasti TH; Owais M
    J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis.
    Owais M; Ahmed I; Krishnakumar B; Jain RK; Bachhawat BK; Gupta CM
    FEBS Lett; 1993 Jul; 326(1-3):56-8. PubMed ID: 8325389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
    Banerjee A; De M; Ali N
    J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
    Shakya N; Sane SA; Haq W; Gupta S
    Parasitol Res; 2012 Aug; 111(2):563-70. PubMed ID: 22392136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.
    Loiseau PM; Imbertie L; Bories C; Betbeder D; De Miguel I
    Antimicrob Agents Chemother; 2002 May; 46(5):1597-601. PubMed ID: 11959611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.
    Prajapati VK; Awasthi K; Yadav TP; Rai M; Srivastava ON; Sundar S
    J Infect Dis; 2012 Jan; 205(2):333-6. PubMed ID: 22158723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis.
    Gupta PK; Jaiswal AK; Asthana S; Verma A; Kumar V; Shukla P; Dwivedi P; Dube A; Mishra PR
    Pharm Res; 2015 May; 32(5):1727-40. PubMed ID: 25425053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.